Selective orexin 2 receptor agonist TAK-925 to treat narcolepsy: results of a randomized, double-blind, placebo-controlled, multiple-ascending-dose, phase 1 study in patients with narcolepsy type 2

被引：0
|
作者：
Tanaka, S. -I. [1 ]
Evans, R. [2 ]
Alexander, R. [2 ]
Imazaki, M. [1 ]
Touno, S. [1 ]
Shimizu, K. [1 ]
Wu, J. [2 ]
Faessel, H. [2 ]
Ratti, E. [2 ]
Hartman, D. [1 ]
机构：
[1] Takeda Pharmaceut Co Ltd, Takeda Dev Ctr Japan, Osaka, Japan
[2] Takeda Pharmaceut Int Co, Neurosci Therapeut Area Unit, Cambridge, MA USA
来源：
JOURNAL OF SLEEP RESEARCH | 2020年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P206
引用
收藏
页码：171 / 172
页数：2
相关论文
共 50 条
  • [1] Selective orexin 2 receptor agonist TAK-925 to treat narcolepsy: results of a randomized, double-blind, placebo-controlled, multiple-ascending-dose, phase 1 study in patients with narcolepsy type 1
    Tanaka, S. -I.
    Evans, R.
    Alexander, R.
    Imazaki, M.
    Touno, S.
    Shimizu, K.
    Wu, J.
    Faessel, H.
    Ratti, E.
    Hartman, D.
    JOURNAL OF SLEEP RESEARCH, 2020, 29 : 72 - 72
  • [2] AN OREXIN 2 RECEPTOR-SELECTIVE AGONIST TAK-925 AMELIORATES NARCOLEPSY-LIKE SYMPTOMS IN OREXIN/ATAXIN-3 MICE
    Suzuki, M.
    Yukitake, H.
    Ishikawa, T.
    Kimura, H.
    SLEEP, 2018, 41 : A1 - A1
  • [3] A PHASE 1 SINGLE ASCENDING DOSE STUDY OF A NOVEL OREXIN 2 RECEPTOR AGONIST, TAK-925, IN HEALTHY VOLUNTEERS (HV) AND SUBJECTS WITH NARCOLEPSY TYPE 1 (NT1) TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMIC OUTCOMES
    Evans, R.
    Tanaka, S.
    Tanaka, S.
    Touno, S.
    Shimizu, K.
    Sakui, S.
    Wu, J.
    Faessel, H.
    Hang, Y.
    Alexander, R.
    Rosen, L.
    Hartman, D.
    SLEEP MEDICINE, 2019, 64 : S105 - S106
  • [4] TAK-925, an orexin 2 receptor-selective agonist, has a threshold plasma concentration to induce arousal in a narcolepsy mouse model.
    Kimura, H.
    Ishikawa, T.
    Hara, H.
    Aoyama, K.
    Yukitake, H.
    Suzuki, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 1223 - 1223
  • [5] TAK-925, AN OREXIN 2 RECEPTOR-SELECTIVE AGONIST, ENHANCED CORTICAL AROUSAL IN A NARCOLEPSY MOUSE MODEL DIFFERENT FROM EFFECTS OF MODAFINIL
    Kimura, H.
    Ishikawa, T.
    SLEEP, 2020, 43 : A56 - A56
  • [6] AN OREXIN 2 RECEPTOR-SELECTIVE AGONIST, TAK-925, AMELIORATES NARCOLEPSY-LIKE SYMPTOMS AND OBESITY IN OREXIN/ATAXIN-3 TRANSGENIC MICE
    Kimura, Haruhide
    Ishikawa, Takashi
    Yukitake, Hiroshi
    Suzuki, Motohisa
    SLEEP, 2019, 42
  • [7] A FOUR-WEEK RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF MAZINDOL ER IN THE TREATMENT OF NARCOLEPSY
    Corser, Bruce
    Stern, Thomas
    Bogan, Richard
    Franco, Jennifer
    Apostol, George
    Konofal, Eric
    Morse, Anne
    Rosenberg, Russell
    Kushida, Clete
    Thorpy, Michael
    SLEEP, 2023, 46 : A257 - A257
  • [8] GLANCE Results of a phase 2, randomized, double-blind, placebo-controlled study
    Goodman, A. D.
    Rossman, H.
    Bar-Or, A.
    Miller, A.
    Miller, D. H.
    Schmierer, K.
    Lublin, F.
    Khan, O.
    Bormann, N. M.
    Yang, M.
    Panzara, M. A.
    Sandrock, A. W.
    NEUROLOGY, 2009, 72 (09) : 806 - 812
  • [9] A DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY IN ADULTS WITH CYSTIC FIBROSIS OF ANABASUM, A SELECTIVE CANNABINOID RECEPTOR TYPE 2 AGONIST
    Chmiel, J.
    Elborn, S.
    Constantine, S.
    White, B.
    PEDIATRIC PULMONOLOGY, 2017, 52 : S317 - S317
  • [10] A Phase 1, Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of HD-6277, a Potent and Selective G-Protein-Coupled Receptor 40 (GPR40) Agonist, in Patients with Type 2 Diabetes Mellitus
    Kim, Ki-Hwan
    Yang, Hye-Jung
    Baek, Myoungki
    DIABETES, 2020, 69
12345